Primary fallopian tube adenocarcinoma in situ associated with adjuvant tamoxifen therapy for breast carcinoma.

We report the first case of primary fallopian tube adenocarcinoma in situ in a patient who had received antiestrogen tamoxifen as adjuvant therapy for breast carcinoma. Clinical and in vivo animal model studies, referable to the possible estrogen agonist effect of tamoxifen on the female genital tract, are also reviewed.